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that patient QoL is maintained following the introduction of
cetuximab plus irinotecan over 12 weeks. However, we must be
mindful of the population of patients assessed/ followed up, the
lack of comparator information and the issues of open label
studies.
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OBJECTIVES: The purpose of this study was to assign utilities to
the three different severity grades of hand-foot-syndrome (HFS)
which is a dose and therapy limiting toxicity in cancer patients
undergoing treatment with e.g. capecitabine, docetaxel, sunitinib
and sorafenib. HFS can develop from mild skin reactions at
hands and feet (grade 1) to major skin reactions with bleeding,
ulceration and severe pain (grade 3). METHODS: In a survey
conducted in a German community pharmacy, randomly chosen
subjects were introduced to the symptoms of HFS using cards
explaining the different HFS grades by pictures of hands and feet,
a clinical deﬁnition and citations of patients. Participants were
asked to imagine suffering from each HFS grade for the next 10
years followed by death. Then they valuated the different grades
using the time-trade-off-method (TTO) and the visual analogue
scale (VAS). RESULTS: Fifty-three participants (30 female =
56.6%, 23 male = 43.4%) valuated the different HFS grades.
Their mean age was 50.8 years (median: 49.0, SD: 18.5, range:
18–86 years). The following mean utilities were assessed using
the TTO: grade 1 = 0.97 (median: 1.00, SD: 0.08), grade
2 = 0.72 (median: 0.80, SD: 0.23) and grade 3 = 0.34 (median:
0.30, SD: 0.22). The VAS resulted in the following mean utilities:
grade 1 = 0.70 (median: 0.70, SD 0.14), grade 2 = 0.37 (median:
0.40, SD: 0.13) and grade 3 = 0.09 (median: 0.10, SD: 0.08). All
differences among the severity grades were statistically signiﬁcant
(p < 0.001). CONCLUSION: The adults questioned see a signiﬁ-
cant impact of the adverse drug reaction HFS on the health status
of patients. Therefore HFS deserves awareness and respect by
health care professionals and requires a high level of patient
information. Furthermore scientists should be encouraged to
conduct more studies concerning prevention and management
of HFS.
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OBJECTIVES: The EQ-5D visual analog scale (VAS) is a patient-
reported rating of overall health that is often reported in clinical
studies. However, few studies are available to guide in the inter-
pretation of meaningful differences in VAS scores. The objective
of this study was to estimate meaningful differences in EQ-5D
VAS scores in cancer, particularly in lung cancer. METHODS:
Secondary data analysis was conducted on a cross sectional study
of 534 cancer patients, including 50 lung cancer patients, who
completed EQ-5D VAS (scaled from 0 (worst imaginable health)
to 100 (best imaginable health)). Anchor-based and distribution
based approaches were used to estimate important differences for
VAS scores. Cancer patients were grouped into clinically mean-
ingful categories anchored by: 1) Eastern Cooperative Oncology
Group performance status (PS), and 2) FACT-G total score-based
quintiles. These anchors were conservative partitions likely to
exceed the true minimum important difference (MID).
Distribution-based criteria applied to each subgroup included 1/2
standard deviation (SD) and the standard error of the measure
(SEM). RESULTS: Estimates of MID for VAS scores based on PS
categories ranged from 8 (average mean difference across catego-
ries) to 11 (SEM) for all cancer patients, and from 8 (0.5 SD) to
12 (average mean difference across PS categories) for lung cancer
patients. Using FACT-G score quintiles, MIDs were the same for
both the overall cancer groups and the lung cancer subgroup
where the average mean difference between quintiles was 7, SEM
was 10 and 1/2 SD was 9. CONCLUSION: The range of esti-
mates representing important differences in EQ-5D VAS scores
was similar between all cancers and lung cancer (7 to 12), with
the lower bounds of MID estimates closer to minimal important
differences, i.e. 7–8. These estimates can help to inform interpre-
tation of EQ-5D VAS scores, particularly in studies of cancer.
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OBJECTIVES: Cancer-related fatigue (CRF) is a frequently
reported complaint in cancer patients and survivors. The Perform
Questionnaire (PQ) is a recently validated scale to assess percep-
tions and beliefs about CRF. This study aims to determine how
sensitive to change is the PQ as well as to compare it with the
sensitivity of the FACT-F. METHODS: An observational and
longitudinal multi-centre study was carried out on a sample of
cancer patients with a moderate level of CRF. PQ and FACT-F
were administered at inclusion and 3 months later, as well as
sociodemographics and key clinical indicators. Patient improve-
ment or worsening related to CRF was assessed by means of a
health status item (HSI) self-administered at the second visit on a
Likert-type ordinal scale with 13 response options. RESULTS:
Baseline patient characteristics (n = 437) were: 60.5% women,
mean age 59.1 years, an average of 2.21 years since diagnosis,
33.6% breast cancer, 54.7% with metastasis, Karnofsky mean
score 80.9, and 29.1% with anaemia. Of the 350 patients who
assessed their change with HSI: 208 (59.4%) reported improve-
ment (‘slightly’ to ‘greatly’), 84 (24%) reported worsening
(‘slightly’ to ‘greatly’), and 58 (16.6%) reported no signiﬁcant
change. The overall PQ score showed a better sensitivity to
clinical deterioration (effect 1.04) than to the improvement
(effect size = 0.57), similar to the magnitude of the effect sizes
obtained with FACT-F (0.91 for deterioration; 0.53 for improve-
ment). The effect sizes of PQ dimensions were also higher for the
patients reporting worsening (ranging from 0.92 to 1.06) than
for those reporting improvements (0.51 to 0.59). CONCLU-
SION: The score of PQ has demonstrated a good level of sensi-
tivity both in patients reporting improvement and in patients
reporting deterioration of health status, in a similar magnitude
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